THURSDAY, Jan. 30, 2014 (HealthDay News) -- For children and
teens with peanut allergies, a new type of treatment might be a
step closer to becoming a reality, according to a preliminary study
The treatment, known as oral immunotherapy, involves eating
small amounts of peanut protein, gradually increasing the amount in
hopes of building up a tolerance to peanuts.
After six months of immunotherapy, 84 percent to 91 percent of
children in the study could safely eat about five peanuts a day --
about 25 times more than they could tolerate before the therapy,
the researchers found.
"Oral immunotherapy has once again shown promise that it may eventually be a treatment for food allergy," said Dr. Matthew Greenhawt, author of an editorial accompanying the study, which was published in the Jan. 30 issue of the journal The Lancet. "But it is still far from being ready for use outside of a research setting.
"There is much work to be done to thoroughly investigate the potential -- both good and bad -- of what oral immunotherapy can achieve," added Greenhawt, an assistant professor at the University of Michigan Food Allergy Center. "But study results like these are encouraging that we may be able to develop a future treatment for food allergy."
Greenhawt said there still are a lot of unknowns, including why
this therapy works, which patients will benefit most and what the
long-term side effects might be.
Dr. Gloria Riefkohl, a pediatrician at Miami Children's
Hospital, echoed Greenhawt's comments.
"I think this is an interesting concept that needs further study," she said. "It's not going to work for all the patients we are seeing. And I don't think it's ready for use in the general population."
Right now, children with peanut allergies are prescribed
epinephrine in the form of an injectable measured dose called an
epinephrine pen, or EpiPen, which they carry with them at all
times, Riefkohl said. Epinephrine is able to quickly counter
anaphylaxis, a life-threatening allergic reaction.
Riefkohl said the new, experimental therapy isn't going to cure
a peanut allergy or let these children indulge in a peanut butter
sandwich. "What we are trying to decrease is the exposure that
usually occurs accidentally and causes difficulty breathing or a
rash or tickling in the mouth," she said.
For the study, a team lead by Dr. Andrew Clark, of Cambridge
University Hospitals, randomly assigned 99 children, aged 7 to 16
years, with varying degrees of peanut allergy to one of two groups.
The first group received 26 weeks of oral immunotherapy; the second
group avoided peanuts or peanut-containing foods altogether.
Avoidance is the current treatment for peanut allergy, the
After six months, 24 of 39 children who received immunotherapy
in the first phase were able to tolerate a daily dose of roughly 10
peanuts, compared with none of the kids in the avoidance group.
In the second phase of the trial, children assigned to avoidance
were offered 26 weeks of immunotherapy followed by a final food
After the second phase, 54 percent of these children passed the
About one-fifth of the kids who had immunotherapy had some mild
reactions to peanuts, including nausea, vomiting, itching in the
mouth, hives and wheezing, the study found. One child needed
epinephrine to quell a severe reaction, and that child withdrew
from the study, the researchers said.
"This treatment allowed children with all severities of peanut allergy to eat large quantities of peanuts -- well above the levels found in contaminated snacks and meals -- freeing them and their parents from the fear of a potentially life-threatening allergic reaction," Clark said in a journal news release. "The families involved in this study say it has changed their lives dramatically."
Study co-author Dr. Pamela Ewan, head of the allergy department
at Cambridge University Hospitals, cautioned parents, however.
"[Oral immunotherapy] is not a treatment people should try on their
own and should only be done by medical professionals in specialist
settings," she said.
Peanut allergy is the most common cause of food-related severe
and life-threatening allergic reactions, according to background
information included in the study.
The U.S National Library of Medicine has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.